APO Research
Talk to an analyst

APO RESEARCH · REPORT

IL-17 Inhibitors for Psoriasis

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global IL-17 Inhibitors for Psoriasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025189 pages

Choose your research edition.

Industry ResearchIL-17 Inhibitors for Psoriasis Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal IL-17 Inhibitors for Psoriasis Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal IL-17 Inhibitors for Psoriasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IL-17 Inhibitors for Psoriasis Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal IL-17 Inhibitors for Psoriasis Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global IL-17 Inhibitors for Psoriasis market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for IL-17 Inhibitors for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for IL-17 Inhibitors for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for IL-17 Inhibitors for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for IL-17 Inhibitors for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of IL-17 Inhibitors for Psoriasis include UCB, Kyowa Kirin, LEO Pharma, Ortho Dermatologics, Jiangsu Hengrui Pharmaceuticals, Eli Lilly, Novartis and Chongqing Genrix Biopharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global IL-17 Inhibitors for Psoriasis market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of IL-17 Inhibitors for Psoriasis and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents IL-17 Inhibitors for Psoriasis sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the IL-17 Inhibitors for Psoriasis market size, projected growth trends, production technologies, key applications, and end-use industries.

IL-17 Inhibitors for Psoriasis Segment by Company

UCB

Kyowa Kirin

LEO Pharma

Ortho Dermatologics

Jiangsu Hengrui Pharmaceuticals

Eli Lilly

Novartis

Chongqing Genrix Biopharmaceutical

IL-17 Inhibitors for Psoriasis Segment by Type

Ixekizumab

Secukinumab

Xeligekimab

Vunakizumab

Brodalumab

Bimelizumab

Other

IL-17 Inhibitors for Psoriasis Segment by Application

Hospital and Clinic

Pharmacy

Other

IL-17 Inhibitors for Psoriasis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IL-17 Inhibitors for Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IL-17 Inhibitors for Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IL-17 Inhibitors for Psoriasis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the IL-17 Inhibitors for Psoriasis market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of IL-17 Inhibitors for Psoriasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of IL-17 Inhibitors for Psoriasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of IL-17 Inhibitors for Psoriasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. IL-17 Inhibitors for Psoriasis Industry Trends Table 2. IL-17 Inhibitors for Psoriasis Industry Drivers Table 3. IL-17 Inhibitors for Psoriasis Industry Opportunities and Challenges Table 4. IL-17 Inhibitors for Psoriasis Industry Restraints Table 5. Global IL-17 Inhibitors for Psoriasis Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Manufacturers (2021-2026) Table 7. Global IL-17 Inhibitors for Psoriasis Sales by Manufacturers (Units) & (2021-2026) Table 8. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Manufacturers Table 9. Global IL-17 Inhibitors for Psoriasis Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global IL-17 Inhibitors for Psoriasis Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global IL-17 Inhibitors for Psoriasis Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global IL-17 Inhibitors for Psoriasis Manufacturers, Product Type & Application Table 13. Global IL-17 Inhibitors for Psoriasis Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global IL-17 Inhibitors for Psoriasis by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Ixekizumab Table 17. Major Manufacturers of Secukinumab Table 18. Major Manufacturers of Xeligekimab Table 19. Major Manufacturers of Vunakizumab Table 20. Major Manufacturers of Brodalumab Table 21. Major Manufacturers of Bimelizumab Table 22. Major Manufacturers of Other Table 23. Global IL-17 Inhibitors for Psoriasis Sales by Type 2021 VS 2025 VS 2032 (Units) Table 24. Global IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (Units) Table 25. Global IL-17 Inhibitors for Psoriasis Sales by Type (2027-2032) & (Units) Table 26. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2021-2026) Table 27. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2027-2032) Table 28. Global IL-17 Inhibitors for Psoriasis Revenue by Type 2021 VS 2025 VS 2032 (Units) Table 29. Global IL-17 Inhibitors for Psoriasis Revenue by Type (2021-2026) & (Units) Table 30. Global IL-17 Inhibitors for Psoriasis Revenue by Type (2027-2032) & (Units) Table 31. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Type (2021-2026) Table 32. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Type (2027-2032) Table 33. Major Manufacturers of Hospital and Clinic Table 34. Major Manufacturers of Pharmacy Table 35. Major Manufacturers of Other Table 36. Global IL-17 Inhibitors for Psoriasis Sales by Application 2021 VS 2025 VS 2032 (Units) Table 37. Global IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (Units) Table 38. Global IL-17 Inhibitors for Psoriasis Sales by Application (2027-2032) & (Units) Table 39. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2021-2026) Table 40. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2027-2032) Table 41. Global IL-17 Inhibitors for Psoriasis Revenue by Application 2021 VS 2025 VS 2032 (Units) Table 42. Global IL-17 Inhibitors for Psoriasis Revenue by Application (2021-2026) & (Units) Table 43. Global IL-17 Inhibitors for Psoriasis Revenue by Application (2027-2032) & (Units) Table 44. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Application (2021-2026) Table 45. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Application (2027-2032) Table 46. Global IL-17 Inhibitors for Psoriasis Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 47. Global IL-17 Inhibitors for Psoriasis Sales by Region (2021-2026) & (Units) Table 48. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Region (2021-2026) Table 49. Global IL-17 Inhibitors for Psoriasis Sales Forecasted by Region (2027-2032) & (Units) Table 50. Global IL-17 Inhibitors for Psoriasis Sales Forecasted Market Share by Region (2027-2032) Table 51. North America IL-17 Inhibitors for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 52. North America IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026) & (Units) Table 53. North America IL-17 Inhibitors for Psoriasis Sales by Country (2027-2032) & (Units) Table 54. Europe IL-17 Inhibitors for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 55. Europe IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026) & (Units) Table 56. Europe IL-17 Inhibitors for Psoriasis Sales by Country (2027-2032) & (Units) Table 57. Asia Pacific IL-17 Inhibitors for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 58. Asia Pacific IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026) & (Units) Table 59. Asia Pacific IL-17 Inhibitors for Psoriasis Sales by Country (2027-2032) & (Units) Table 60. South America, Middle East and Africa IL-17 Inhibitors for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 61. South America, Middle East and Africa IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026) & (Units) Table 62. South America, Middle East and Africa IL-17 Inhibitors for Psoriasis Sales by Country (2027-2032) & (Units) Table 63. Global IL-17 Inhibitors for Psoriasis Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global IL-17 Inhibitors for Psoriasis Revenue by Region (2021-2026) & (US$ Million) Table 65. Global IL-17 Inhibitors for Psoriasis Revenue by Region (2027-2032) & (US$ Million) Table 66. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Region (2021-2026) Table 67. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Region (2027-2032) Table 68. UCB Company Information Table 69. UCB Business Overview Table 70. UCB IL-17 Inhibitors for Psoriasis Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. UCB IL-17 Inhibitors for Psoriasis Product Portfolio Table 72. UCB Recent Development Table 73. Kyowa Kirin Company Information Table 74. Kyowa Kirin Business Overview Table 75. Kyowa Kirin IL-17 Inhibitors for Psoriasis Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Kyowa Kirin IL-17 Inhibitors for Psoriasis Product Portfolio Table 77. Kyowa Kirin Recent Development Table 78. LEO Pharma Company Information Table 79. LEO Pharma Business Overview Table 80. LEO Pharma IL-17 Inhibitors for Psoriasis Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. LEO Pharma IL-17 Inhibitors for Psoriasis Product Portfolio Table 82. LEO Pharma Recent Development Table 83. Ortho Dermatologics Company Information Table 84. Ortho Dermatologics Business Overview Table 85. Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Ortho Dermatologics IL-17 Inhibitors for Psoriasis Product Portfolio Table 87. Ortho Dermatologics Recent Development Table 88. Jiangsu Hengrui Pharmaceuticals Company Information Table 89. Jiangsu Hengrui Pharmaceuticals Business Overview Table 90. Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Product Portfolio Table 92. Jiangsu Hengrui Pharmaceuticals Recent Development Table 93. Eli Lilly Company Information Table 94. Eli Lilly Business Overview Table 95. Eli Lilly IL-17 Inhibitors for Psoriasis Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Eli Lilly IL-17 Inhibitors for Psoriasis Product Portfolio Table 97. Eli Lilly Recent Development Table 98. Novartis Company Information Table 99. Novartis Business Overview Table 100. Novartis IL-17 Inhibitors for Psoriasis Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Novartis IL-17 Inhibitors for Psoriasis Product Portfolio Table 102. Novartis Recent Development Table 103. Chongqing Genrix Biopharmaceutical Company Information Table 104. Chongqing Genrix Biopharmaceutical Business Overview Table 105. Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Product Portfolio Table 107. Chongqing Genrix Biopharmaceutical Recent Development Table 108. Key Raw Materials Table 109. Raw Materials Key Suppliers Table 110. IL-17 Inhibitors for Psoriasis Distributors List Table 111. IL-17 Inhibitors for Psoriasis Customers List Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. IL-17 Inhibitors for Psoriasis Product Image Figure 2. Global IL-17 Inhibitors for Psoriasis Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global IL-17 Inhibitors for Psoriasis Market Size (2021-2032) & (US$ Million) Figure 4. Global IL-17 Inhibitors for Psoriasis Sales (2021-2032) & (Units) Figure 5. Global IL-17 Inhibitors for Psoriasis Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 IL-17 Inhibitors for Psoriasis Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Ixekizumab Image Figure 9. Secukinumab Image Figure 10. Xeligekimab Image Figure 11. Vunakizumab Image Figure 12. Brodalumab Image Figure 13. Bimelizumab Image Figure 14. Other Image Figure 15. Global IL-17 Inhibitors for Psoriasis Sales by Type (2021 VS 2025 VS 2032) & (Units) Figure 16. Global IL-17 Inhibitors for Psoriasis Sales Market Share 2021 VS 2025 VS 2032 Figure 17. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2021-2032) Figure 18. Global IL-17 Inhibitors for Psoriasis Revenue by Type (2021 VS 2025 VS 2032) & (Units) Figure 19. Global IL-17 Inhibitors for Psoriasis Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Type (2021-2032) Figure 21. Hospital and Clinic Image Figure 22. Pharmacy Image Figure 23. Other Image Figure 24. Global IL-17 Inhibitors for Psoriasis Sales by Application (2021 VS 2025 VS 2032) & (Units) Figure 25. Global IL-17 Inhibitors for Psoriasis Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2021-2032) Figure 27. Global IL-17 Inhibitors for Psoriasis Revenue by Application (2021 VS 2025 VS 2032) & (Units) Figure 28. Global IL-17 Inhibitors for Psoriasis Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Application (2021-2032) Figure 30. North America IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 31. North America IL-17 Inhibitors for Psoriasis Sales Market Share by Country (2021-2032) Figure 32. U.S. IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 33. Canada IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 34. Mexico IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 35. Europe IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 36. Europe IL-17 Inhibitors for Psoriasis Sales Market Share by Country (2021-2032) Figure 37. Germany IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 38. France IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 39. U.K. IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 40. Italy IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 41. Netherlands IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 42. Asia Pacific IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 43. Asia Pacific IL-17 Inhibitors for Psoriasis Sales Market Share by Country (2021-2032) Figure 44. China IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 45. Japan IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 46. South Korea IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 47. Southeast Asia IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 48. India IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 49. Australia IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 50. South America, Middle East and Africa IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 51. South America, Middle East and Africa IL-17 Inhibitors for Psoriasis Sales Market Share by Country (2021-2032) Figure 52. Brazil IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 53. South Africa IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 54. Saudi Arabia IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 55. Turkey IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 56. Argentina IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 57. UAE IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 58. Egypt IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 59. Chile IL-17 Inhibitors for Psoriasis Sales and Growth Rate (2021-2032) & (Units) Figure 60. Global IL-17 Inhibitors for Psoriasis Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Figure 63. North America IL-17 Inhibitors for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Figure 65. Europe IL-17 Inhibitors for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific IL-17 Inhibitors for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa IL-17 Inhibitors for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. IL-17 Inhibitors for Psoriasis Value Chain Figure 71. Manufacturing Cost Structure Figure 72. IL-17 Inhibitors for Psoriasis Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Ixekizumab
  • Secukinumab
  • Xeligekimab
  • Vunakizumab
  • Brodalumab
  • Bimelizumab
  • Other
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • UCB
  • Kyowa Kirin
  • LEO Pharma
  • Ortho Dermatologics
  • Jiangsu Hengrui Pharmaceuticals
  • Eli Lilly
  • Novartis
  • Chongqing Genrix Biopharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global IL-17 Inhibitors for Psoriasis Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global IL-17 Inhibitors for Psoriasis Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global IL-17 Inhibitors for Psoriasis Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global IL-17 Inhibitors for Psoriasis Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global IL-17 Inhibitors for Psoriasis Market Dynamics
  1. 2.1 IL-17 Inhibitors for Psoriasis Industry Trends
  2. 2.2 IL-17 Inhibitors for Psoriasis Industry Drivers
  3. 2.3 IL-17 Inhibitors for Psoriasis Industry Opportunities and Challenges
  4. 2.4 IL-17 Inhibitors for Psoriasis Industry Restraints
3 IL-17 Inhibitors for Psoriasis Market by Manufacturers
  1. 3.1 Global IL-17 Inhibitors for Psoriasis Revenue by Manufacturers (2021-2026)
  2. 3.2 Global IL-17 Inhibitors for Psoriasis Sales by Manufacturers (2021-2026)
  3. 3.3 Global IL-17 Inhibitors for Psoriasis Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global IL-17 Inhibitors for Psoriasis Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global IL-17 Inhibitors for Psoriasis Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global IL-17 Inhibitors for Psoriasis Manufacturers, Product Type & Application
  7. 3.7 Global IL-17 Inhibitors for Psoriasis Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global IL-17 Inhibitors for Psoriasis Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 IL-17 Inhibitors for Psoriasis Players Market Share by Revenue in 2025
  11. 3.8.3 2025 IL-17 Inhibitors for Psoriasis Tier 1, Tier 2, and Tier 3
4 IL-17 Inhibitors for Psoriasis Market by Type
  1. 4.1 IL-17 Inhibitors for Psoriasis Type Introduction
  2. 4.1.1 Ixekizumab
  3. 4.1.2 Secukinumab
  4. 4.1.3 Xeligekimab
  5. 4.1.4 Vunakizumab
  6. 4.1.5 Brodalumab
  7. 4.1.6 Bimelizumab
  8. 4.1.7 Other
  9. 4.2 Global IL-17 Inhibitors for Psoriasis Sales by Type
  10. 4.2.1 Global IL-17 Inhibitors for Psoriasis Sales by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global IL-17 Inhibitors for Psoriasis Sales by Type (2021-2032)
  12. 4.2.3 Global IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2021-2032)
  13. 4.3 Global IL-17 Inhibitors for Psoriasis Revenue by Type
  14. 4.3.1 Global IL-17 Inhibitors for Psoriasis Revenue by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global IL-17 Inhibitors for Psoriasis Revenue by Type (2021-2032)
  16. 4.3.3 Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Type (2021-2032)
5 IL-17 Inhibitors for Psoriasis Market by Application
  1. 5.1 IL-17 Inhibitors for Psoriasis Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global IL-17 Inhibitors for Psoriasis Sales by Application
  6. 5.2.1 Global IL-17 Inhibitors for Psoriasis Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global IL-17 Inhibitors for Psoriasis Sales by Application (2021-2032)
  8. 5.2.3 Global IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2021-2032)
  9. 5.3 Global IL-17 Inhibitors for Psoriasis Revenue by Application
  10. 5.3.1 Global IL-17 Inhibitors for Psoriasis Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global IL-17 Inhibitors for Psoriasis Revenue by Application (2021-2032)
  12. 5.3.3 Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Application (2021-2032)
6 Global IL-17 Inhibitors for Psoriasis Sales by Region
  1. 6.1 Global IL-17 Inhibitors for Psoriasis Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global IL-17 Inhibitors for Psoriasis Sales by Region (2021-2032)
  3. 6.2.1 Global IL-17 Inhibitors for Psoriasis Sales by Region (2021-2026)
  4. 6.2.2 Global IL-17 Inhibitors for Psoriasis Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America IL-17 Inhibitors for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America IL-17 Inhibitors for Psoriasis Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe IL-17 Inhibitors for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe IL-17 Inhibitors for Psoriasis Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific IL-17 Inhibitors for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific IL-17 Inhibitors for Psoriasis Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa IL-17 Inhibitors for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa IL-17 Inhibitors for Psoriasis Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global IL-17 Inhibitors for Psoriasis Revenue by Region
  1. 7.1 Global IL-17 Inhibitors for Psoriasis Revenue by Region
  2. 7.1.1 Global IL-17 Inhibitors for Psoriasis Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global IL-17 Inhibitors for Psoriasis Revenue by Region (2021-2026)
  4. 7.1.3 Global IL-17 Inhibitors for Psoriasis Revenue by Region (2027-2032)
  5. 7.1.4 Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America IL-17 Inhibitors for Psoriasis Revenue (2021-2032)
  8. 7.2.2 North America IL-17 Inhibitors for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe IL-17 Inhibitors for Psoriasis Revenue (2021-2032)
  11. 7.3.2 Europe IL-17 Inhibitors for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific IL-17 Inhibitors for Psoriasis Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific IL-17 Inhibitors for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa IL-17 Inhibitors for Psoriasis Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa IL-17 Inhibitors for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 UCB
  2. 8.1.1 UCB Company Information
  3. 8.1.2 UCB Business Overview
  4. 8.1.3 UCB IL-17 Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 UCB IL-17 Inhibitors for Psoriasis Product Portfolio
  6. 8.1.5 UCB Recent Developments
  7. 8.2 Kyowa Kirin
  8. 8.2.1 Kyowa Kirin Company Information
  9. 8.2.2 Kyowa Kirin Business Overview
  10. 8.2.3 Kyowa Kirin IL-17 Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Kyowa Kirin IL-17 Inhibitors for Psoriasis Product Portfolio
  12. 8.2.5 Kyowa Kirin Recent Developments
  13. 8.3 LEO Pharma
  14. 8.3.1 LEO Pharma Company Information
  15. 8.3.2 LEO Pharma Business Overview
  16. 8.3.3 LEO Pharma IL-17 Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 LEO Pharma IL-17 Inhibitors for Psoriasis Product Portfolio
  18. 8.3.5 LEO Pharma Recent Developments
  19. 8.4 Ortho Dermatologics
  20. 8.4.1 Ortho Dermatologics Company Information
  21. 8.4.2 Ortho Dermatologics Business Overview
  22. 8.4.3 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Product Portfolio
  24. 8.4.5 Ortho Dermatologics Recent Developments
  25. 8.5 Jiangsu Hengrui Pharmaceuticals
  26. 8.5.1 Jiangsu Hengrui Pharmaceuticals Company Information
  27. 8.5.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  28. 8.5.3 Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Product Portfolio
  30. 8.5.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  31. 8.6 Eli Lilly
  32. 8.6.1 Eli Lilly Company Information
  33. 8.6.2 Eli Lilly Business Overview
  34. 8.6.3 Eli Lilly IL-17 Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly IL-17 Inhibitors for Psoriasis Product Portfolio
  36. 8.6.5 Eli Lilly Recent Developments
  37. 8.7 Novartis
  38. 8.7.1 Novartis Company Information
  39. 8.7.2 Novartis Business Overview
  40. 8.7.3 Novartis IL-17 Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novartis IL-17 Inhibitors for Psoriasis Product Portfolio
  42. 8.7.5 Novartis Recent Developments
  43. 8.8 Chongqing Genrix Biopharmaceutical
  44. 8.8.1 Chongqing Genrix Biopharmaceutical Company Information
  45. 8.8.2 Chongqing Genrix Biopharmaceutical Business Overview
  46. 8.8.3 Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Product Portfolio
  48. 8.8.5 Chongqing Genrix Biopharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 IL-17 Inhibitors for Psoriasis Value Chain Analysis
  2. 9.1.1 IL-17 Inhibitors for Psoriasis Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 IL-17 Inhibitors for Psoriasis Production Mode & Process
  6. 9.2 IL-17 Inhibitors for Psoriasis Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 IL-17 Inhibitors for Psoriasis Distributors
  9. 9.2.3 IL-17 Inhibitors for Psoriasis Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst